In the 1960s, the first antiandrogen, or androgen antagonist, was discovered. Antiandrogens antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT). Antiandrogens are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia. Antiandrogens are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and salivary duct carcinoma and that antiandrogens can potentially be used to treat it.

Property Value
dbo:abstract
  • In the 1960s, the first antiandrogen, or androgen antagonist, was discovered. Antiandrogens antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT). Antiandrogens are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia. Antiandrogens are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and salivary duct carcinoma and that antiandrogens can potentially be used to treat it. As of 2010 antiandrogens are small molecules and can be either steroidal or non-steroidal depending on ligand chemistry. Steroidal antiandrogens share a similar steroid structure, while non-steroidal antiandrogens (NSAAs) may have structurally distinctive pharmacophores. Only a limited number of compounds are available for clinical use despite the fact that a very large variety of antiandrogen compounds have been discovered and researched. (en)
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 32986449 (xsd:integer)
dbo:wikiPageRevisionID
  • 743995337 (xsd:integer)
dbp:align
  • center
dbp:alt
  • Bicalutamide
  • Cyproterone acetate
  • Hydroxyflutamide
  • Nilutamide
dbp:caption
  • Bicalutamide
  • Cyproterone acetate
  • Hydroxyflutamide
  • Nilutamide
dbp:footer
  • Figure 7: Basic structures of current antiandrogens
dbp:headerAlign
  • center
dbp:image
  • Bicalutamide_-_R2.jpg
  • Hydroxyflutamide_-_R.jpg
  • Nilutamide_-_R.jpg
dbp:width
  • 140 (xsd:integer)
  • 160 (xsd:integer)
  • 170 (xsd:integer)
  • 300 (xsd:integer)
dct:subject
rdfs:comment
  • In the 1960s, the first antiandrogen, or androgen antagonist, was discovered. Antiandrogens antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT). Antiandrogens are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia. Antiandrogens are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and salivary duct carcinoma and that antiandrogens can potentially be used to treat it. (en)
rdfs:label
  • Discovery and development of antiandrogens (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of